Open AccessReport on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2020–2021
Author(s) -
Genevieve O’Neill,
Ammar Aziz,
Miku Kuba,
Sook Kwan Brown,
Hilda Lau,
Sally Soppe,
Mariana Baz,
Heidi Peck,
YiMo Deng,
Kanta Subbarao,
Ian Barr
Publication year - 2020
Publication title -
communicable diseases intelligence
Language(s) - English
Resource type - Journals
ISSN - 2209-6051
DOI - 10.33321/cdi.2022.46.63
Subject(s) - zanamivir , virology , neuraminidase , oseltamivir , embryonated , virus , h5n1 genetic structure , biology , pandemic , antigenic drift , hemagglutinin (influenza) , neuraminidase inhibitor , influenza a virus , medicine , covid-19 , infectious disease (medical specialty) , disease , pathology
As part of its role in the World Health Organization's (WHO) Global Influenza Surveillance and Response System (GISRS), the WHO Collaborating Centre for Reference and Research on Influenza in Melbourne received a total of 2,393 human influenza positive samples between 1 January 2020 and 31 December 2021 (2020: n = 2,021 samples; 2021: n = 372 samples). Viruses were analysed for their antigenic, genetic and antiviral susceptibility properties. Selected viruses were propagated in qualified cells or embryonated hen's eggs for potential use in seasonal influenza virus vaccines. During 2020-2021, influenza A viruses (A(H1N1)pdm09 in 2020 and A(H3N2) in 2021) predominated over influenza B viruses. In 2020, the majority of A(H1N1)pdm09, A(H3N2) and influenza B viruses analysed at the Centre were found to be antigenically similar to the respective WHO recommended vaccine strains for the southern hemisphere in 2020. In 2021, the majority of A(H1N1)pdm09 and A(H3N2) viruses were found to be antigenically distinct relative to the WHO recommended vaccine strains for the southern hemisphere in 2021. Of the influenza B viruses analysed at the Centre, 46.7% were found to be antigenically distinct to the respective WHO recommended vaccine strains. Of 1,538 samples tested for susceptibility to the neuraminidase inhibitors oseltamivir and zanamivir (in 2020, n = 1,374; in 2021, n = 164), two A(H1N1)pdm09 viruses showed highly reduced inhibition against oseltamivir, and one A(H1N1)pdm09 virus showed highly reduced inhibition against zanamivir. All of these samples were received in 2020.